Traceable platinum(II) complexes with alkylene diamine-derived ligands: synthesis, characterization and in vitro studies

Diiodido- (6a/6b) and dichloridoplatinum(II) complexes (7a/7b) with fluorescent ligands 2-[(2-aminoethyl)amino]ethyl-2-(methylamino)benzoate (5a) and 2-amino-1-(aminoethyl)ethyl-2-(methylamino)benzoate (5b) were prepared and characterized by elemental analysis, ESI-MS analysis, fluorescence spectrom...

Full description

Saved in:
Bibliographic Details
Published inJournal of coordination chemistry Vol. 71; no. 2; pp. 243 - 257
Main Authors Walther, Till, Herzog, Renate, Kaluđerović, Milena R., Wagner, Christoph, Schmidt, Harry, Kaluđerović, Goran N.
Format Journal Article
LanguageEnglish
Published Abingdon Taylor & Francis 17.01.2018
Taylor & Francis Ltd
Subjects
Cancer
Chemotherapy
Cisplatin
Colon
Coordination compounds
cytotoxicity
Fluorescence
Ligands
NMR
NMR spectroscopy
Nuclear magnetic resonance
Platinum
platinum(II) complexes
Online AccessGet full text

Cover

More Information
Summary:Diiodido- (6a/6b) and dichloridoplatinum(II) complexes (7a/7b) with fluorescent ligands 2-[(2-aminoethyl)amino]ethyl-2-(methylamino)benzoate (5a) and 2-amino-1-(aminoethyl)ethyl-2-(methylamino)benzoate (5b) were prepared and characterized by elemental analysis, ESI-MS analysis, fluorescence spectrometry, as well as 1 H, 13 C, and 195 Pt NMR spectroscopy. All compounds have been tested against A2780 ovarian cancer, A549 lung carcinoma, and HT-29 colon cancer cell lines using sulforhodamine-B assay. The activity increased from ligand precursors, diiodido- to dichloridoplatinum(II) complexes, except against HT-29 cell line where diiodido and dichlorido expressed similar activity. These compounds enter the tumor cells and emit a bright fluorescence at ca. 470 nm, mainly targeting nuclei.
ISSN:0095-8972
1029-0389
DOI:10.1080/00958972.2018.1431392